Co-Diagnostics, Inc. to Present at Robins Equity Research Roundup 2017
September 25 2017 - 7:30AM
Business Wire
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or
the “Company”), a molecular diagnostics company with a unique,
proprietary platform for the development of diagnostic tests,
announced today that it will be presenting at the Third Annual
Robins Equity Research Roundup, held September 25 – 27, 2017 near
Portland, Oregon.
Sponsored by Catalyst Research Management Group, RIA, the Equity
Research Roundup offers an opportunity for individual investors and
professional money managers to become acquainted with up-and-coming
public and private companies. Presenters represent a range of
industries, and the goals of the conference also include
facilitating an environment for the management of these companies
to introduce themselves to influential members of the investment
community. Co-Diagnostics CEO Dwight Egan will be presenting at
7:30 am PDT on September 26th.
Mr. Egan remarked: “We are excited for the opportunity to kick
off this year’s Equity Research Roundup. Marc Robins’ experience
advocating for newly public and micro-cap companies provides an
ideal environment for Co-Diagnostics to present our story to key
players in the finance world, and we anticipate that it will
resonate with those participants looking for a micro-cap investment
prospect with our potential.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that has developed and intends to manufacture
and sell reagents used for diagnostic tests that function via the
detection and/or analysis of nucleic acid molecules (DNA or RNA),
and to sell diagnostic equipment from other manufacturers as
self-contained lab systems.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Readers of this press release
are cautioned not to place undue reliance on any forward-looking
statements. The Company does not undertake any obligation to update
any forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
Disclaimer:
This news release does not constitute an offer to sell or a
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170925005490/en/
Co-DiagnosticsAndrew Benson, Investor
Relations801-438-1036investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024